Health Care • Biotechnology: Pharmaceutical Preparations
$7.72 ▼ -0.26
(-3.26%)
MKT CAP: $500.1M • VOL: 156.7K
52W L $7 52W H $40
ROARABLE / RQD
D- • 39/100
PIOTROSKI
2 / 9
MPLT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$169.1M | -$82.9M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$161.2M | -$77.6M |
| EBITDA (Normalized) | -$168.7M | -$82.3M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$138.1M | -$78.8M |
| Capital Expenditures (CapEx) | $473.0K | $770.0K |
| Free Cash Flow (FCF) | -$138.6M | -$79.6M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -32.4% | -45.0% |
| Cash & Short-Term Equivalents | $46.7M | $38.3M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $458.4M | -$193.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MPLT.